{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hyponatraemia/background-information/causes/","result":{"pageContext":{"chapter":{"id":"2f18ae19-5934-5b36-8f56-cfbc5010c984","slug":"causes","fullItemName":"Causes","depth":2,"htmlHeader":"<!-- begin field 632634bc-91c0-497c-8916-a76900acfa82 --><h2>What causes it?</h2><!-- end field 632634bc-91c0-497c-8916-a76900acfa82 -->","summary":"","htmlStringContent":"<!-- begin item 289550de-b56a-4052-bd9b-a76900acf948 --><!-- begin field f21a7955-b115-41f7-b1e1-a76900acfa82 --><ul><li style=\"box-sizing: inherit;\"><strong>The cause of hyponatraemia is often multifactorial <strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Reynolds, 2006</a>]</strong> <strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">GAIN, 2010</a>]</strong>.</strong></li><li style=\"box-sizing: inherit;\"><strong>Hypotonic (or true) hyponatraemia </strong>can result from a range of clinical conditions that can be categorized by their effect on extracellular fluid volume [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">GAIN, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Saeed, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Spasovski, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Dineen, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">BMJ, 2019</a>]:<ul><li><strong>Hypovolemic (volume depletion) hyponatraemia </strong>occurs when the total body water and sodium content are both decreased but the relative decrease in total body sodium is greater than the decrease in total body water. Causes include:<ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/causes/#additional-information-on-causes\">Medications</a>, especially thiazide diuretics.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/causes/#additional-information-on-causes\">Endocrine disorders</a> (primary adrenal insufficiency).</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/causes/#additional-information-on-causes\">Cerebral salt-wasting</a> (a rare cause of hyponatraemia resulting from a central nervous system insult such as aneurysmal subarachnoid haemorrhage).</li><li>Severe diarrhoea and/or vomiting (gastrointestinal sodium loss).</li><li>Sweating (for example during <a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/causes/#additional-information-on-causes\">exercise</a>) and extensive skin burns (transdermal sodium loss).</li><li>Salt-wasting nephropathies, for example tubulopathy after chemotherapy.</li><li>Third space losses — bowel obstruction, pancreatitis, severe hypoalbuminaemia, sepsis, or muscle trauma.</li></ul></li><li><strong><strong>Hypervolemic </strong>(volume overload) <strong>hyponatraemia </strong></strong>occurs when the total body water and sodium content both increase but the relative increase in total body water is greater than the increase in total body sodium, resulting in oedema. Causes include:<ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/causes/#additional-information-on-causes\">Congestive heart failure</a>.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/causes/#additional-information-on-causes\">Liver disease</a> (cirrhosis with ascites).</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/causes/#additional-information-on-causes\">Kidney disease</a> (acute kidney injury, chronic kidney disease, nephrotic syndrome).</li></ul></li><li><strong>Euvolemic (normal volume status) <strong>hyponatraemia </strong></strong>occurs when the total body water increases but the total body sodium remains unchanged, thereby producing a dilutional effect. Causes include:<ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/causes/#additional-information-on-causes\">Drugs</a> (for example selective serotonin-reuptake inhibitors and thiazide diuretics).</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/causes/#additional-information-on-causes\">Syndrome of inappropriate antidiuretic hormone secretion</a> (SIADH).</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/causes/#additional-information-on-causes\">Endocrine disorders</a> (secondary adrenal insufficiency and hypothyroidism [very rare cause]).</li><li>High water low solute intake — <a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/causes/#additional-information-on-causes\">primary polydipsia</a>, anorexia nervosa, and beer potomania (excess beer consumption with a low solute diet).</li></ul></li></ul></li><li><strong>Pseudo-hyponatraemia </strong>is an artifactually (falsely) low serum sodium concentration due to hyperproteinaemia (multiple myeloma is the most common cause) or hypertriglyceridaemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Sahay, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">BMJ, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Jones, 2019</a>].</li><li><strong>Hypertonic (or hyperosmolar) hyponatraemia</strong> can be caused by severe hyperglycaemia (the high levels of glucose draw intracellular water into the extracellular space) or administration of an active osmolyte (such as mannitol) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Ball, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Sahay, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">BMJ, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Jones, 2019</a>].</li></ul><!-- end field f21a7955-b115-41f7-b1e1-a76900acfa82 --><!-- end item 289550de-b56a-4052-bd9b-a76900acf948 -->","topic":{"id":"0a0a0516-fca2-530d-88cd-096861572e3a","topicId":"560440de-b2ae-4ea7-9fb2-a701015e193f","topicName":"Hyponatraemia","slug":"hyponatraemia","lastRevised":"Last revised in November 2020","chapters":[{"id":"2d0342b8-1d8f-5b76-af1d-5c62137a465c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"94ef9729-defa-5118-80c3-603843005f8a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0e655e55-4b6c-5ca3-9d0a-bcf5afa498d8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"262d0445-6fa5-53ed-8b8c-037da1983e4f","slug":"changes","fullItemName":"Changes"},{"id":"f79882a4-6b50-5264-a45b-2d43249a3418","slug":"update","fullItemName":"Update"}]},{"id":"8705184f-c02d-5cb2-9294-d85860c5d56e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"815d5ca9-eab9-5381-8a01-784808ab6cc7","slug":"goals","fullItemName":"Goals"},{"id":"85b3dae2-f267-5123-913e-442f138841bb","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"80e3ca36-d509-55eb-a763-7ccfa16bcafa","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e5a45e73-9ef1-5cc7-9cee-cd7c7219e953","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9b557451-4a38-5431-a228-8e1d27043742","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3c76bef5-59b5-5e3e-b95c-72fd0f7370fb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2dda3afa-6384-564b-9938-f26680c7b906","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c2b54f92-5f73-5871-be34-52c87c49e81f","slug":"definition","fullItemName":"Definition"},{"id":"336f0b50-af95-5811-8819-05ebe4104ffb","slug":"pathophysiology","fullItemName":"Pathophysiology"},{"id":"2f18ae19-5934-5b36-8f56-cfbc5010c984","slug":"causes","fullItemName":"Causes"},{"id":"475e9aa0-653a-537b-988e-7f4bcf86f27a","slug":"incidence-prevelance","fullItemName":"Incidence and prevelance"},{"id":"f9af97ee-3a11-59b0-9533-e9a4ed3f8900","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"8887725e-10a2-544c-8f35-8094785500e3","slug":"complications","fullItemName":"Complications"}]},{"id":"1fb71225-29dc-5a7a-a4e6-edf212ae9225","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6c1bda17-ccd5-52a4-9299-93f536f69e45","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"abaaf6cd-c698-507a-8fe7-feb15605c044","slug":"assessing-a-person-with-hyponatraemia","fullItemName":"Assessing a person with hyponatraemia"}]},{"id":"3f1780bb-24f2-5fae-a374-4de7113ad17f","fullItemName":"Management","slug":"management","subChapters":[{"id":"bf8b2972-5f8b-587a-935c-8f4a06208987","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"23dd936f-0ccd-5303-9c4d-504c43e5f8c8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5b75e52d-5896-50b9-9baf-e0fe2b5acf38","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6c996d4b-7572-5b4c-8adb-efc4b888b240","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a0a19e6f-1376-5caf-95d6-5492111dbefe","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"73af9656-0aa1-53b8-b41a-855898c14f79","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f9132882-237e-5da1-86ef-fac89422fbc6","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0c67dc74-d944-572d-9995-f93fb7844ef9","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6781f94c-c836-5a66-b9df-5ef91879b82b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2dda3afa-6384-564b-9938-f26680c7b906","slug":"background-information","fullItemName":"Background information"},"subChapters":[{"id":"45dda7d8-a5d0-5724-8429-58454c4e8dc1","slug":"additional-information-on-causes","fullItemName":"Additional information on causes","depth":3,"htmlHeader":"<!-- begin field 209a4f36-58d5-48fa-a674-ac720172aabb --><h3>Additional information on causes of hyponatraemia?</h3><!-- end field 209a4f36-58d5-48fa-a674-ac720172aabb -->","summary":null,"htmlStringContent":"<!-- begin item 61cc70c1-6382-452d-8444-27f7d15e3886 --><!-- begin field 6116f153-6402-4c93-bbb8-ac720172aabb --><h5>Medications</h5><ul><li><strong>Medications can cause hyponatraemia by affecting the homeostasis of sodium and water (for example diuretics) or by increasing the production, or potentiating the action, of </strong><strong><a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/pathophysiology/\">antidiuretic hormone</a></strong><strong> (ADH), leading to medication-induced </strong><strong><a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/causes/#additional-information-on-causes\">syndrome of inappropriate antidiuretic hormone secretion</a></strong> <strong>(SIADH).</strong></li><li><strong>The most common medications associated with hyponatraemia include</strong><strong> </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Saeed, 2014</a>]</strong><strong> </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Woodward, 2018</a>]</strong><strong> </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">BMJ, 2019</a>]</strong> <strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Jones, 2019</a>]</strong><strong>:</strong><ul><li>Diuretics — all types of diuretics have been associated with hyponatraemia, but thiazides and thiazide-like diuretics are the most common cause [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Spasovski, 2014</a>].<ul><li>Thiazide and thiazide-like diuretics inhibit sodium chloride reabsorption in the distal tubules [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Saeed, 2014</a>].</li><li>Loop diuretics may also cause hyponatraemia, but this is more likely to occur when they are taken in combination with medications, such as angiotensin converting enzyme (ACE) inhibitors or spironolactone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Jacob, 2019</a>]. Loop diuretics inhibit sodium chloride reabsorption in the ascending loop of Henle [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Saeed, 2014</a>].</li><li>Hyponatraemia may appear within days or even years of starting treatment, but will generally resolve once treatment is discontinued [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">BMJ, 2019</a>].</li></ul></li><li>Selective serotonin reuptake inhibitors (SSRIs) — SSRIs (especially citalopram) are more frequently associated with hyponatraemia than other antidepressants [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Woodward, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Jacob, 2019</a>]. <ul><li>The reported incidence of hyponatraemia caused by SSRI use varies widely from 0.5–32%. Hyponatraemia usually develops within the first few weeks of treatment and resolves within 2 weeks of stopping the drug.</li><li>Older age and concurrent use of diuretics are the most important risk factors for development of SSRI-associated hyponatraemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Liamis, 2008</a>].</li></ul></li><li>Antipsychotics (such as haloperidol and phenothiazines).</li><li>Carbamazepine — the incidence varies widely from 4.8–41.5% depending on the population studied. It is more frequent in the elderly or when concurrently used with diuretics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Liamis, 2008</a>] or antipsychotics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Yamamoto, 2019</a>].</li></ul></li><li><strong>Less common causes include [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Saeed, 2014</a>] <strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">BMJ, 2019</a>]</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Jones, 2019</a>]:</strong><ul><li>Drugs that increase the production, or potentiate the action, of ADH (SIADH):<ul><li>Opioids.</li><li>ACE inhibitors and angiotensin-II receptor antagonists (AIIRAs).</li><li>Proton pump inhibitors (such as omeprazole and lansoprazole).</li><li>Anticonvulsants (such as sodium valproate, lamotrigine, and leviteracetam).</li><li>Amiodarone.</li><li>Theophylline.</li><li>Dopamine antagonists (metoclopramide and domperidone).</li><li>Antidiabetics (insulin, chlorpropamide, and tolbutamine).</li><li>Nonsteroidal anti-inflammatory drugs.</li><li>MDMA (ecstasy).</li></ul></li><li>Drugs that cause loss of ADH inhibition (SIADH):<ul><li>Nonsteroidal anti-inflammatory drugs (particularly in combination with thiazide diuretics or heart failure).</li></ul></li><li>Drugs that produce exogenous ADH:<ul><li>Desmopressin.</li><li>Oxytocin.</li></ul></li></ul></li></ul><h5>Heart failure</h5><ul><li><strong>Hyponatraemia in heart failure is primarily caused by a low cardiac output </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Leier, 1994</a>]</strong><strong>. </strong>Although there is an increase in plasma volume in heart failure, the effective circulating arterial volume is depleted and this stimulates sodium and water retention by the release of ADH, renin (subsequently leading to increases in angiotensin II), and noradrenaline.</li><li>Hyponatraemia occurs in approximately 20–30% of people with chronic heart failure New York Heart Association classes III and IV [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Goldberg, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Gheorghiade, 2007</a>].</li><li>The reduction in cardiac output may cause hyponatraemia through non-osmotic stimulation of ADH release [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Goh, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Reynolds, 2005</a>].</li></ul><h5>Liver disease</h5><ul><li><strong>Hyponatraemia is thought to occur in approximately 30% of people admitted to hospital with advanced liver cirrhosis. </strong>In an outpatient setting, the prevalence is suggested to be around 15% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Upadhyay, 2006</a>].</li><li>Hyponatraemia in liver failure may be triggered by reduced effective arterial blood volume from systemic vasodilation and arteriovenous shunting of blood. The reduced effective blood volume can activate baroreceptor-mediated ADH release leading to water retention [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Spasovski, 2014</a>].</li></ul><h5>Kidney disease</h5><ul><li><strong>Conditions causing chronic kidney disease (such as polycystic kidney disease and chronic pyelonephritis) can result in a sodium-losing nephropathy state </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Goh, 2004</a>]</strong><strong>. </strong>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a>.</li><li>In nephrotic syndrome, blood volume may be reduced (due to lower serum oncotic pressure) causing ADH secretion with subsequent development of hyponatraemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Spasovski, 2014</a>].</li><li>The reduction in renal function may cause hyponatraemia through non-osmotic stimulation of ADH release [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Goh, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Reynolds, 2005</a>].</li></ul><h5>Cerebral salt-wasting (CSW)</h5><ul><li><strong>CSW</strong><strong> is a rare cause of hyponatraemia and has been reported in people with intracranial disease (for example subarachnoid haemorrhage, traumatic brain injury, or intracranial surgery).</strong></li><li>It is thought to be the result of elevated levels of atrial and/or brain natriuretic peptide, which causes an increase in sodium and water excretion [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Lien, 2007</a>].</li></ul><h5>Third spacing</h5><ul><li>Third spacing occurs when too much fluid moves from the blood vessels into the interstitial or 'third\" space' (the nonfunctional area between cells) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Holcomb, 2008</a>].</li><li>Bowel obstruction, pancreatitis, sepsis, or muscle trauma may markedly reduce effective circulating blood volume through fluid leakage from blood vessels. The reduced effective blood volume can activate baroreceptor-mediated ADH release leading to water retention [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Spasovski, 2014</a>]. </li></ul><h5>SIADH</h5><ul><li>SIADH is characterized by excessive unsuppressible release of ADH either from the posterior pituitary gland, or an abnormal non-pituitary source [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Barbar, 2013</a>]. The excessive action of ADH produces a state of water excess without major sodium retention [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Jacob, 2019</a>].</li><li>SIADH is a common cause of hyponatraemia and can result from malignancy (for example small cell lung cancer, gastrointestinal tract cancers), central nervous system disorders (for example subarachnoid haemorrhage, meningitis, encephalitis), pulmonary disease (for example pneumonia), or other non-specific causes (for example medications, pain, nausea, stress, general anaesthesia). It can also be idiopathic [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">BMJ, 2019</a>].</li><li>Diagnostic features include [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">BMJ, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Jones, 2019</a>]:<ul><li>Euvolemia.</li><li>Urine osmolality greater than 100 mOsm/kg.</li><li>Urine sodium greater than 30 mmol/L.</li><li>Normal renal, adrenal (9 am cortisol), and thyroid function.</li></ul></li></ul><h5>Reset osmostat syndrome </h5><ul><li><strong>Reset osmostat, a subtype of SIADH, is a rare cause of hyponatraemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Vale, 2015</a>].</strong></li><li>It is due to secretion of ADH at a lower plasma osmolality. Consequently, the corrective mechanism to re-establish normal serum sodium concentration occurs at a lower threshold, resulting in persistent and stable hyponatraemia.</li><li>It has been identified as a cause of chronic, stable hyponatraemia in pregnancy, quadriplegia, psychosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Siegel, 2008</a>], and other chronic conditions, such as tuberculosis, encephalitis, malnutrition, and malignancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Elisaf, 1996</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Goh, 2004</a>].</li></ul><h5>Endocrine disorders</h5><ul><li><strong>Endocrine disorders are an uncommon cause of hyponatraemia</strong> <strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Goh, 2004</a>]</strong><strong>.</strong></li><li>In primary adrenal insufficiency, hyponatraemia is partly explained by mineralocorticoid deficiency, which results in increased excretion of sodium in the urine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Reynolds, 2005</a>]. A combination of hyponatraemia and hyperkalaemia is suggestive of Addison's disease. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/addisons-disease/\">Addison's disease</a> for more information.</li><li>Glucocorticoid deficiency is probably the most important factor causing hyponatraemia in hypopituitarism. Elderly people with secondary adrenal insufficiency are particularly prone to developing hyponatraemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Reynolds, 2005</a>].</li><li>Severe hypothyroidism very rarely causes hyponatraemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Kilpatrick, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Spasovski, 2014</a>]. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypothyroidism/\">Hypothyroidism</a> for more information.</li></ul><h5>Exercise</h5><ul><li><strong>Exercise-associated hyponatraemia is hyponatraemia occurring during, or up to 24 hours after, prolonged physical exertion (for example running a marathon) </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Hew-Butler, 2019</a>]</strong><strong> </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Bennett, 2020</a>]</strong><strong>.</strong></li><li>The primary mechanism leading to the majority of cases is overconsumption of hypotonic fluids, likely in combination with non-osmotic stimulation of ADH secretion.</li><li>In most people who develop hyponatremia during prolonged exertional activities (such as endurance athletic events, backpacking, and hiking), there is an increase in total body water relative to total body exchangeable sodium. Hyponatremia occurs by ingestion of large amounts of hypotonic fluids (water or sports drinks) in excess of sweat, urine, and insensible (mainly respiratory and gastrointestinal) losses [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Bennett, 2020</a>].</li><li>Most cases do not require intervention, but a small number may present with severe and life-threatening hyponatraemia.</li><li>People more at risk include females and those with a low body weight. Concurrent use of nonsteroidal anti-inflammatory drugs (NSAIDs) has also been associated with increased risk of developing exercise-associated hyponatraemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Rosner, 2009</a>].</li></ul><h5>Primary polydipsia </h5><ul><li><strong>Primary polydipsia is thought to be caused by a central defect in thirst regulation. </strong></li><li>The osmotic threshold for thirst is reduced below the threshold for the release of ADH, encouraging people to continue to drink despite a low <a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/diagnosis/assessing-a-person-with-hyponatraemia/#interpreting-investigation-results\">plasma osmolality</a> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Schrier, 2006</a>].</li><li>It is seen in 6–20% of people with a psychiatric disorder. This may be caused by a dry mouth from anticholinergic medications or be a function of the underlying psychiatric disorder [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Jose, 1979</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Blum, 1983</a>].</li></ul><!-- end field 6116f153-6402-4c93-bbb8-ac720172aabb --><!-- end item 61cc70c1-6382-452d-8444-27f7d15e3886 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}